Deutsche Bank initiated coverage on Abcam with a new price target
$ABCM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Deutsche Bank initiated coverage of Abcam with a rating of Hold and set a new price target of $15.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/20/2023 | $23.00 → $22.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 6/16/2023 | $25.00 | Neutral → Buy | BofA Securities |
| 12/14/2022 | $15.00 | Hold | Deutsche Bank |